<DOC>
	<DOCNO>NCT00216346</DOCNO>
	<brief_summary>Symptomatic Visceral Leishmaniasis ( VL ) fatal ; Due increase resistance standard therapy antimonials , need new safe , efficacious , low-cost therapy treatment VL . Paromomycin off-patent aminoglycoside antibiotic anti-leishmaniasis activity . This study test safety efficacy paromomycin treatment patient VL India .</brief_summary>
	<brief_title>Safety Efficacy Study Paromomycin Treat Visceral Leishmaniasis</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>Age 555 year ( inclusive ) either gender . Newly diagnose VL VL treatment failure confirm spleen bone marrow aspirate . Clinical sign symptom compatible VL : fever two week duration splenomegaly . Biochemical haematological test value follow : Haemoglobin &gt; 5.0g/100mL White blood cell count &gt; 1 x109/L Platelet count &gt; 50 x 109/L AST , ALT alkaline phosphatase &lt; 3 time upper normal limit Prothrombin time &lt; 5 second control Serum creatinine level within normal limit Serum potassium level within normal limit HIV negative A history intercurrent concurrent disease ( e.g . chronic alcohol consumption drug addiction ; renal , hepatic , cardiovascular central nervous system disease ; diabetes ; tuberculosis infectious major psychiatric disease ) may introduce variable affect outcome study . Any condition investigator think may prevent patient complete study therapy subsequent followup . An abnormal baseline audiogram ( presentation 75 dB high 8KHz ) and/or history significant vestibular auditory dysfunction . Proteinuria ( &gt; 2+ ) . A history allergy hypersensitivity aminoglycosides . A history major surgery within last two week . Pregnancy lactation . [ Note : woman childbearing age must use adequate form contraception ( document ) agree period sexual abstinence treatment phase study . ] Previous treatment VL within two week enrolment study . Prior treatment failure paromomycin amphotericin B .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>